RegMed Investors’ (RMi) pre-open: Think about it …

August 5, 2025 7:46am

One of the biggest problems with the cell and gene therapy sector is 99% of them have no earnings! It’s all about hope of a cure…

Earnings are the highlight of the week: Beam Therapeutics (BEAM), Supernus Pharmaceuticals (SUPN) <Acquired Sage Therapeutics (SAGE), AxoGen (AXGN) and Ultragenyx Pharmaceuticals (RARE). Last night release: Cellectis SA (CLLS) and CRISPR Therapeutics (CRSP) <see The Bottom Line>

Pre-open Signals: 2 Positive, 1 Negative and 2 Sell into Strength Indications

My interpretation of the morning’s numbers is written to be informative; it’s built on what happened to make “it” happen today

Never leave an investor uninformed … I say what others won’t, so you can do what others can’t!

Remember that overnight and pre-open actions’ futures and markets doesn’t necessarily translate into actual trading in today’s market session.

RMi enhances sector knowledge by signaling how these “posts” fit into the spectrum of share pricing and translated into “positions” that can be confirmed or refuted

Monday’s night’s … RegMed Investors (RMi) Closing Bell: Yippie yi yo kayah … https://www.regmedinvestors.com/articles/14047

RegMed Investors (RMi) Research Note: Harvard Apparatus GT (OTCQB): Sustaining a Loser … https://www.regmedinvestors.com/articles/13812

Tuesday: The pre-open Dow futures are UP +0.02% or (+9 points), the S&P futures are UP +0.24% or (+15 points) and the Nasdaq futures are UP +0.36% or (+83 point)

Futures inch <barely> higher Tuesday, 8/5

Europe markets climbed,

Asia-Pacific markets traded mostly higher

Henry’omics: We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies

• Monday: The Dow closed UP +585.06 points or +1.34%, the S&P closed UP +91.93 points or +1.47% while the Nasdaq closed UP +403.45 points or +1.95%
• Friday: The Dow closed DOWN -542.40 points or -1.23%, the S&P closed DOWN -101.38 points or -1.60% while the Nasdaq closed DOWN -472.32 points or -2.24%
• The past week, the Dow tumbled -2.9% <its worst week since April 4>, the S&P 500 dropped -2.4% <for its worst weekly performance since May 23> and the Nasdaq lost -2.2

Economic Data Docket: U.S. trade deficit – June, S&P final U.S. services PMI – July and ISM services

Q3 – August - 1 negative and 1 positive closes

• July – 1 market holiday, 13 positive and 9 negative closes

Coverage Dropped: bluebird bio (BLUE) Private Equity acquired, Blueprint Medicine (BPMC) acquired by SNY, Homology Medicine (FIXX), Sage Therapeutics (SAGE) acquired by SUPN, Verve Therapeutics (VERV) – acquired by LLY

Added: BioNTech (BNTX), Sarepta Therapeutics (SRPT), Supernus Pharma (SUPN), IQVIA Holdings (IQV) and Wave Life Sciences Ltd. (WVE)

Companies in my headlights – It’s your decision; I provide ideas and context

I post about “indication intelligence” looking toward investment conferences … to assist investors with insight into sector vulnerabilities and strengths.  A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

• I’ll pass; …. an escape in the making of more econs, earnings, ups, downs and just plain uncertainty

Although:

AxoGen (AXGN) closed down -$0.12 with a positive +$0.45 or +3.59% pre-open along with earnings release

Alnylam Pharmaceuticals (ALNY) closed up +$17.76 after Friday’s +$9.56, Thursday’s +$52.44, Wednesday’s +$9.25, last Tuesday’s +$5.76 and the previous Monday’s -$4.02 with a positive +$2.95 or +0.70% pre-open – SELL into Strength

Moderna (MRNA) closed up +$0.03 after Friday’s -$1.95 with earnings release after Thursday’s -$2.59 with a positive +$0.18 or +0.65% pre-open

CRISPR Therapeutics (CRSP) closed up +$3.50 after Friday’s -$0.17, Thursday’s -$1.42, Wednesday’s -$1.34, last Tuesday’s -$4.73 and the previous Monday’s -$1.01 with a negative -$8.32 or -13.96% pre-open 

Prime Medicine (PRME) closed up +$0.46 after Friday’s +$0.30) – public offering closed with a positive +$0.02 or +0.44% pre-open – SELL into Strength

The BOTTOM LINE: US stock futures held steady regaining index and the cell and gene therapy sector share pricing “upside” after a tumultuous week and braced for the next wave of corporate earnings

• e are here on Tuesday ...
• On Monday, stocks sharply rebounded after tanking on Friday in the aftermath of a number of market-shaking events, including a weak jobs report, fresh tariffs, new signs of rising prices, and the firing of the commissioner of the Bureau of Labor Statistics.
• President Trump continued to ramp-up pressure on trade, threatening to hike tariffs on India.
• Broader economic news will flavor the coming days, as investors eye Wednesday's release of the Fed's preferred inflation gauge, the Personal Consumer Expenditures (PCE) index, to see the impact of tariffs on the general public's "core" expenses. An initial reading on first quarter US GDP is also due Wednesday. 

August begins as July ends: understand the “flow” …

• 8/4 – Monday closed positive with 27 positive, 8 negative and 0 flats
• 8/1 – Friday closed negative with 9 positive, 20 negative and 6 flats

Last Week:

• 7/31 - Thursday closed negative with 3 positive, 25 negative and 7 flats
• 7/30 - Wednesday closed negative with 12 positive, 18 negative and 5 flats
• 7/29 – Tuesday closed negative with 8 positive, 22 negative and 5 flats
• 7/28 – Monday closed negative with 14 positive, 16 negative and 5 flats

Earnings are the highlight of the week:

8/6 – Wednesday Sarepta Therapeutics (SRPT), 8/7 Thursday = Intellia Therapeutics (NTLA), Regenxbio (RGNX) and 8/11, Monday = Agenus (AGEN)

• Meeting earnings expectation and/or missing consensus will deem share pricing outcomes this week.

Earnings to date:

Added today:

• Cellectis SA (CLLS) a net loss of -$18.1 M or -$0.24 per share, revenue of $30.2 M, a cash position of $230 M and a runway until 2H/27.
•  CRISPR Therapeutics (CRSP) a net loss of -$208.5 M or -$2.40 per share, revenue of $45.2 M, a cash position of $1.7 B and a N/A runway

Previous:

• Moderna (MRNA) a net loss of -$0.8 B, or -$2.13 per share with revenue of $142 M, an R&D and an SG&A decrease and a cash position of $7.5 B with a runway until 2026 <beats revenue estimate and earnings consensus>.
• Sage Therapeutics (SAGE): net loss of -$49.7 M or -$0.79 per share, revenue of $23.2M, a cash position of $366 M – acquired
• Vericel (VCEL): net loss of -$0.06 M or -$0.01 per share, revenue of $63.2M, a cash position of $164 M and a runway until 2027
• Alnylam Pharmaceuticals (ALNY): net loss of -$66.3 M or -$0.51 per share, revenue of $773.7 M, a cash position of $2.86 B and a N/A runway
• Lenz Therapeutics (LENZ): net loss of -$14.9 M or -$0.53 per share, revenue of $5 M, a cash position of $209.6 M and a runway until 2026
• uniQure NV (QURE): a net loss of -$37.7 M, or -$0.69 per share with revenue of $5.3 M, an R&D increase and an SG&A decrease and a cash position of $377.7 M with a runway until 2H/27 <missed revenue estimate and consensus>
• Ionis Pharmaceuticals (IONS): a net income of +124 M, or +$0.70 per share with revenue of $452 M, and a cash position of $2.3 B with a runway until FY28 < estimate and consensus beats>
• MiMedx (MDXG): a net income of +$100 M or +$0.06 per share with revenue of $99 M and a cash position of $100 M with a runway until 2026.

“I also hate to be so negative or contrarian but, this is a NO spin zone and truth is its product; I can always be WRONG but, I am mostly EARLY!”

Reiterating, “There are always some big ifs, especially given some of the headlines that could emanate after a past few months of news flatulence.

• As always, I brace myself for earnings associated with share pricing volatility, some economics and tariff developments and their effects?

Welcome to my world of defining the “grey’ in our universe!

• I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities.

 I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed.